USANA Health Sciences Inc (USNA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of USANA Health Sciences Inc stock $20.37, price $13.63, upside +49.4%, quality 62 out of 100. Rating: undervalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $12.86 – $103.74 · fair‑value band $18.80 – $21.47 · the $13.63 price screens below the $20.37 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow USANA Health Sciences in your weekly email
Every Wednesday you see whether USANA Health Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer.
Show moreShow less
The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration.
It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online.
The company was founded in 1992 and is headquartered in Salt Lake City, Utah.
Stock analysis
USANA Health Sciences Inc (USNA) currently trades at $13.63, while our model-based Fair Value estimate is $20.37, implying the stock looks roughly 33% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $49.11 per share, and 16 of the 23 models we run sit above the $13.63 price.
Bear case: the Asset-Based group reads lowest at $4.25, and 7 of the 23 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $18.80 (bear) to $21.47 (bull), the price of $13.63 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
USANA Health Sciences Inc reported revenue of $925M in FY2025 versus $1.2B in FY2021, a compound −6.0%/yr. Reported net income was $10.8M in FY2025, compounding −44.9%/yr from FY2021.
Key figures
Market cap $252M Micro · P/S ratio 0.28 · EPS (TTM) $−1.14 · Net margin −2.3% · Return on equity −5.1% · Return on assets (EBIT) 15.6% (5-year average) · Operating margin −0.7% · Revenue (TTM) $906M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (medium confidence).
What moves the price
The share trades about 41% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −1% fair-value upside, at 49%, USNA screens cheaper than that median.
Fair Value models
Bear$18.80Fair Value $20.37Bull$21.47
Price $13.63 · Upside +49.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 5 officers or directors sold shares worth $543,895 and none bought.
SaleBrent NeidigCHIEF COMMERCIAL OFFICER2× since Jun 12, 2026: 7,513 shares, avg. $19.67$147,758Jun 16, 2026
SalePaul A. JonesCHIEF PEOPLE OFFICER2× since May 28, 2026: 12,374 shares, avg. $18.75$231,985Jun 8, 2026
SaleJohn Turman FlemingDirector2,450 shares at $17.93$43,929Jun 1, 2026
SaleG Doug IiekkingCHIEF FINANCIAL OFFICER5,360 shares at $18.75$100,500May 27, 2026
SaleGilbert A FullerDirector2× since Mar 20, 2026: 2,115 shares, avg. $17.83$37,710May 22, 2026
SaleJoshua FoukasCHIEF LEGAL OFFICER2× since Feb 20, 2026: 8,252 shares, avg. $20.65$170,380May 7, 2026
SalePeter BenedictCHIEF INFORMATION OFFICER2× since Dec 10, 2025: 7,226 shares, avg. $19.96$144,236Mar 3, 2026
SaleDavid Mulham MulhamCHIEF SALES OFFICER873 shares at $21.00$18,333Dec 10, 2025
SaleFrederic J WinssingerDirector2,000 shares at $19.21$38,420Nov 10, 2025
Plus 16 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+8.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.0%
Start year 2020 (pandemic). Over 10 years: +0.1% a year
Revenue growth 31 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−35.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−35.9%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−36.8% vs −16.7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 6%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +3.0% a year for the price.
News mood ⓘNews mood, the average tone of recent news (89 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Compare USANA Health Sciences Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 625 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside+49.4% · Top 25%
Profitability
Return on assets1.5% · Below median
Net margin (12 months)−2.3% · Bottom 25%
Operating margin (12 months)−0.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−3.6% · Bottom 25%
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "USANA Health Sciences Inc Fair Value". https://www.fairvalue-calculator.com/stock/USNA
Frequently asked questions
Is USANA Health Sciences Inc (USNA) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $20.37 versus a price of $13.63, about +49% upside (undervalued).
What is the fair value of USNA?
Our model-based fair value for USANA Health Sciences Inc is $20.37 (as of Nov 6, 2026), built from audited fundamentals. The current price: $13.63.
What is the quality score of USNA?
USANA Health Sciences Inc has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for USANA Health Sciences Inc (USNA)?
Our model-based price target is the fair value of $20.37 (as of Nov 6, 2026) from 23 valuation models. Cautious scenario $18.80, optimistic scenario $21.47. It is a calculation from audited fundamentals, not an analyst target.
What is the USANA Health Sciences Inc stock forecast for 2026?
Our models put fair value at $20.37, about +49% upside versus a price of $13.63 (undervalued). Cautious scenario $18.80, optimistic scenario $21.47. The calculation is refreshed regularly with new filings.
What is the revenue of USANA Health Sciences Inc (USNA)?
USANA Health Sciences Inc reported trailing-twelve-month revenue of about $906M (latest available figure, as of Nov 6, 2026).
What growth is priced into USANA Health Sciences Inc (USNA)?
For today's price to be fair in a discounted-cash-flow model, USANA Health Sciences Inc would have to grow free cash flow by +5.4 % per year for five years (discount rate 11.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -4.0 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of USNA use?
Our models discount USANA Health Sciences Inc at 11.7 %: a base by market capitalisation (micro), damped by beta 0.67, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For USANA Health Sciences Inc that is +5.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.7 %) and the same formula as our fair value.
How much growth has USANA Health Sciences Inc (USNA) delivered so far?
Over the past 5 years revenue at USANA Health Sciences Inc grew -4.0 % a year. The price currently implies free-cash-flow growth of +5.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of USANA Health Sciences Inc (USNA) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into USANA Health Sciences Inc (+5.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of USANA Health Sciences Inc (USNA)?
The free-cash-flow yield on the price is 3.38 %: that much free cash flow USANA Health Sciences Inc produces per unit of market value. When it exceeds the discount rate of our models (11.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of USANA Health Sciences Inc (USNA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For USANA Health Sciences Inc it is $20.37 per share (as of Nov 6, 2026), against a price of $13.63. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is USANA Health Sciences Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, USNA trades below its calculated fair value: price $13.63, fair value $20.37, a gap of about +49% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of USNA?
No. The price is what the market pays today ($13.63); the fair value is what the company's own numbers justify ($20.37). For USANA Health Sciences Inc the two are $6.74 per share apart. That gap is exactly why we show both numbers side by side.
How much is USANA Health Sciences Inc worth?
The market values USANA Health Sciences Inc at about $252M (market capitalisation, as of Nov 6, 2026). Per share that is $13.63; our models calculate a fair value of $20.37 per share.
What do the bullish and bearish scenarios say about USNA?
Our models span a range for USANA Health Sciences Inc: cautious scenario $18.80, base $20.37, optimistic $21.47 per share (as of Nov 6, 2026, price $13.63). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of USNA?
The PEG ratio of USANA Health Sciences Inc is 0.67 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of USANA Health Sciences Inc (USNA)?
Balance-sheet figures for USANA Health Sciences Inc (as of Nov 6, 2026): return on equity −5.1%. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is USNA from its 52-week high?
USANA Health Sciences Inc trades at $13.63, about 41% below its 52-week high of $23.24 and 6% above the low of $12.86 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $20.37 is for.
Which stocks are comparable to USANA Health Sciences Inc?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is USANA Health Sciences Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $13.63, calculated fair value $20.37 (+49%), Quality Score 62/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of USNA calculated?
We run USANA Health Sciences Inc through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $20.37 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. USANA Health Sciences Inc currently trades 33% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of USANA Health Sciences Inc (USNA)?
The closing price on Nov 6, 2026 was $13.63. Our model-based fair value is $20.37, about +49% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with USANA Health Sciences Inc right now?
The price is below even our cautious bear case ($18.80). The market is more pessimistic than our downside scenario. Solid quality (62/100) at a price below fair value, the discount is the argument here, not the business quality. The models converge in a tight band ($18.80 to $21.47), unusually little disagreement for a valuation.
Where does the earnings growth of USANA Health Sciences Inc (USNA) come from?
Earnings per share at USANA Health Sciences Inc grew −5.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.6 %, EBIT margin −6.7 %, tax rate −2.8 %, residual (interest, one-offs) +0.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of USANA Health Sciences Inc
How large is the market capitalisation of USANA Health Sciences Inc (USNA)?
The market capitalisation of USANA Health Sciences Inc is $252M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of USANA Health Sciences Inc (USNA)?
The price-to-sales ratio of USANA Health Sciences Inc is 0.28 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of USANA Health Sciences Inc (USNA)?
Earnings per share at USANA Health Sciences Inc are $−1.14. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of USANA Health Sciences Inc (USNA)?
The net margin of USANA Health Sciences Inc is −2.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of USANA Health Sciences Inc (USNA)?
The return on equity (ROE) of USANA Health Sciences Inc is −5.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of USANA Health Sciences Inc (USNA)?
On an EBIT basis the return on assets of USANA Health Sciences Inc is 15.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of USANA Health Sciences Inc (USNA)?
The operating margin of USANA Health Sciences Inc is −0.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at USANA Health Sciences Inc (USNA)?
Revenue at USANA Health Sciences Inc is growing −3.6% versus a year earlier (3y avg −2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at USANA Health Sciences Inc (USNA)?
Earnings per share at USANA Health Sciences Inc are growing −16.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does USANA Health Sciences Inc (USNA) hold?
USANA Health Sciences Inc holds more cash than debt, $144M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch USANA Health Sciences Inc in the live analysis
One click puts USANA Health Sciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026